Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers vaccines that include Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used as an additive to influenza vaccines; and SARS (D3252), which is used as an antigen for severe acute respiratory syndrome (SARS) virus. It also provides baculovirus expression vector system for prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applications; expresSF+ cells, and insect cell line that is used in the production of proteins; GeneXpress, which provides ...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Compensation as of Fiscal Year 2013.
Protein Sciences Corporation Key Developments
Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM
Apr 9 14
Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM. Venue: Grand Hyatt, Tokyo, Japan.
Protein Sciences Corporation Announces Availability of Flublok Influenza Vaccine
Nov 13 13
Protein Sciences Corporation announced that doses for the 2013-14 season have been released by the FDA and are now available. Quantities of Flublok are limited and will be distributed on a first-come, first-served basis exclusively by FFF Enterprises. Flublok, a cutting-edge class of influenza vaccine called RIV3 (recombinant hemagglutinin influenza vaccine, trivalent formulation), is made by making just the active ingredient needed for protection without growing influenza virus. The vaccine contains 3 times the protective ingredient in traditional flu vaccines. The CDC recommends the use of Flublok for all adults 18-49 years old and specifically for those in that age range who have a known or suspected egg allergy, regardless of severity. Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.
Protein Sciences Corporation Announces First Doses of Flublok Influenza Vaccine
Oct 10 13
Protein Sciences Corporation announced that they expect the first doses of Flublok influenza vaccine for the 2013/2014 season to be released in time for vaccinations to occur prior to Thanksgiving. According to the Centers for Disease Control and Prevention (CDC), influenza activity typically peaks in January or later. It takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, so it is best that people get vaccinated before then. Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2013